Article
Biochemical reconstitution of temozolomide-induced mutational processes.
The Journal of biological chemistry - 1 Nov 2025
Sanyal Mahima R, Sugiyama Tomohiko
Abstract excerpt
Temozolomide (TMZ), a DNA alkylator, is a chemotherapeutic agent for brain tumors, but the treatment induces a distinct pattern of mutations, known as a cancer mutational signature single-base substitution signature 11 (SBS11). Although the correlation between TMZ treatment and SBS11 mutations is very clear, the precise biochemical mechanisms that cause SBS11 have not been elucidated. TMZ can alkylate DNA at...
Topics
Join the communities discussing this publication.
